ngshrd | 906
BRCAness with HRD
Keywords
BRCA1, BRCA2, BRCAness, Genomic Instability Score, GIS, Homologous Recombination Deficiency, HRD, HRR, MyChoice, Myriad, Next-Generation Sequenzierung, Next Generation Sequencing, Ovarian cancer, Ovarian carcinoma
| Material |
|
|
| Note |
Mutations in >50 genes associated with BRCAness (incl. BRCA1, BRCA2, PALB2) and evaluation of the Genomic Instability Score (GIS)(TruSight Oncology 500 HRD powered by Myriad) To order this analysis, please contact us via contact@viollier.ch or 0848 121 121. This analysis may result in excess information. This will be communicated, unless it is noted otherwise when placing the order. Since in rare cases there may also be indications of hereditary changes, the GUMG shall arrange for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent). Tarification: according to Tardoc |
|
| Duration | 14 days | |
| Frequency | 1 x per week | |
| Method | Next Generation Sequencing | |
| Price | CHF 0.00 | |
| Tariff | 0.00 TP |
Team of consultants
|
Dr. med.
Katharina Marston
FMH Pathology, molecular pathology
|
FMH Pathology, molecular pathology | T |
|
|
Dr. rer. nat.
Henriette Kurth
FAMH Specialist in laboratory medicine, medical genetics
|
FAMH Specialist in laboratory medicine, medical genetics | T |
|
|
Dr. med.
Jean-François Egger
FMH pathology
|
FMH pathology | T |
|
|
Dr. phil. II
Christoph Noppen
FAMH Specialist in laboratory medicine, medical genetics
|
FAMH Specialist in laboratory medicine, medical genetics | T |
|
|
Dr. med.
Santiago Giménez de Mestral
FMH pathology, cytopathology
|
FMH pathology, cytopathology | T |
|